Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Concerns Swirl Over Critical Drug Launch

By Dave Williamson - Apr 4, 2013 at 7:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can this pharmaceutical company shake lingering safety profile fears?

In the following video, Motley Fool health-care analyst David Williamson discusses Ariad Pharmaceuticals (NASDAQ: ARIA), as the company's stock reverses direction today, up 3% following yesterday's tumble. He notes the results of a boutique institutional research survey that found Ariad's new drug Iclusig to have toxicity concerns, and even more negative information coming from the FDA, citing blood clots and liver toxicity. David tells investors what the potential for this drug is, and whether it has a shot at success on the market despite these safety concerns.

Stocks Mentioned

Merck & Co., Inc.

MRK

$93.75 (-0.94%) $0.89

Bristol Myers Squibb Company

$91.25 (-0.74%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

How Vaccine Cash Could Fuel Pfizer's Future Growth

This High-Powered Growth Stock Just Beat Earnings and Is Trading Near Its 52-Week Low

2 Dividend Kings That Are Soundly Beating the Market in 2022

2 Struggling Growth Stocks That Could Double Your Money

This Growth Stock Expects Sales to Rise by at Least 51% This Year

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

322%

S&P 500 Returns

116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.